查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1696288

全球数位化糖尿病管理市场 - 2025 年至 2033 年

Global Digital Diabetes Management Market - 2025-2033
出版日期: | 出版商: DataM Intelligence | 英文 180 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

2024 年全球数位糖尿病管理市场规模达 145.8 亿美元，预计到 2033 年将达到 332.6 亿美元，2025-2033 年预测期内的复合年增长率为 9.7%。

全球数位糖尿病管理市场利用设备、软体和服务等数位技术来改善糖尿病管理和监测。这包括连续血糖监测仪（CGM）、胰岛素帮浦、行动应用程式和基于云端的平台等工具。这些技术共同收集、分析和共享患者健康指标的资料，提供即时见解，使患者和医疗保健提供者能够就糖尿病管理做出明智的决策。该市场旨在帮助患者更好地控制血糖水平，减少併发症，并改善整体健康。

市场动态：

驱动因素与约束因素

糖尿病数位健康领域的技术进步

技术进步在推动数位糖尿病管理市场成长方面发挥关键作用。连续血糖监测仪 (CGM)、智慧胰岛素帮浦、穿戴式装置和人工智慧糖尿病管理应用程式等创新正在改变糖尿病的监测和管理方式。这些技术提供有关血糖水平的即时、个人化资料，使患者和医疗保健提供者能够做出更明智的决策。例如，人工智慧和巨量资料分析有助于改进胰岛素输送演算法并提供个人化的治疗建议，改善短期和长期糖尿病管理。

技术进步透过提供有效的糖尿病管理工具彻底改变了糖尿病护理。一个关键点是持续维持最佳血糖水平。数位健康工具，包括连网胰岛素笔、便携式 A1C 监测器和行动应用程序，使患者更容易在医院外管理糖尿病。这些行动应用程式允许医疗保健提供者根据即时资料创建个人化的治疗计划，确保更好地控制血糖水平并可能降低长期健康风险。

糖尿病管理的另一个突破是自动胰岛素输送（AID）系统，它结合了连续血糖监测仪（CGM）和胰岛素泵，可以根据即时血糖资料自动调整胰岛素水平。该系统可以更精确地控制血糖水平，并减轻患者的负担。此外，便携式 A1C 监测仪可以让人们在家中测量他们的 A1C 水平，为评估长期糖尿病控制提供重要指标。这些进步对个人化护理做出了巨大贡献，使患者能够更好地管理病情，减少去医院的次数。

例如，2024 年 2 月，Kakao Healthcare 推出了一款名为 PASTA（个人化、可访问、支援性、技术支援和实惠）的新型 AI 糖尿病管理应用程式。该应用程式旨在帮助糖尿病和其他慢性疾病患者更有效地管理他们的健康。它与持续血糖监测 (CGM) 设备（例如 i-SENS 的 CareSens Air 和 Dexcom 的 G7）集成，提供血糖水平的即时资料。所有这些因素都要求全球数位化糖尿病管理市场的发展。

设备和技术成本高昂

设备和技术的高成本仍然是全球数位糖尿病管理市场发展的重大限制。根据美国国家生物技术资讯中心 (NCBI) 2024 年 7 月的资料，胰岛素帮浦、连续血糖监测仪 (CGM) 和其他先进的数位工具可能非常昂贵，一些胰岛素帮浦的价格在 4,500 美元至 6,500 美元之间，不包括相关消耗品。这个价格对患者来说可能是一个障碍，特别是那些没有医疗保险的患者，限制他们获得基本糖尿病管理技术。

此外，儘管这些设备透过提供即时资料和更好地控制血糖水平来改善患者的治疗效果，但研究表明，与每日多次注射（MDI）相比，胰岛素帮浦可能并不总是最具成本效益的选择，尤其是对于 1 型糖尿病患者而言。因此，全球糖尿病管理市场正在迅速扩张。上述因素限制了市场的成长。

目录

第一章：市场介绍和范围

  • 报告目标
  • 报告范围和定义
  • 报告范围

第 2 章：高阶主管见解与关键要点

  • 市场亮点和战略要点
  • 主要趋势和未来预测
  • 按产品类型分类的片段
  • 按模式分类的片段
  • 最终用户的程式码片段
  • 按地区分类的片段

第 3 章：动态

  • 影响因素
    • 驱动程式
      • 糖尿病数位健康领域的技术进步
      • 糖尿病盛行率上升
    • 限制
      • 设备和技术成本高昂
      • 资料隐私和安全问题
    • 机会
      • 新兴市场扩张
    • 影响分析

第四章：战略洞察与产业展望

  • 市场领导者和先驱者
    • 新兴先锋和杰出参与者
    • 拥有最大销售品牌的既定领导者
    • 拥有成熟产品的市场领导者
  • CXO 观点
  • 最新进展与突破
  • 案例研究/正在进行的研究
  • 监管和报销情况
    • 北美洲
    • 欧洲
    • 亚太地区
    • 拉丁美洲
    • 中东和非洲
  • 波特五力分析
  • 供应链分析
  • 专利分析
  • SWOT 分析
  • 未满足的需求和差距
  • 市场进入和扩张的推荐策略
  • 情境分析：最佳情况、基本情况和最坏情况预测
  • 定价分析和价格动态
  • 关键意见领袖

第 5 章：数位糖尿病管理市场（依产品类型）

  • 智慧型血糖仪
  • 持续血糖监测 (CGM) 系统
  • 智慧胰岛素笔
  • 智慧胰岛素泵
  • 胰岛素贴片和闭环泵
  • 其他的

第 6 章：数位糖尿病管理市场（按模式划分）

  • 穿戴
  • 手持式

第 7 章：数位糖尿病管理市场（按最终用户划分）

  • 家庭护理设置
  • 医院和糖尿病诊所
  • 其他的

第 8 章：数位糖尿病管理市场，按区域市场分析和成长机会

  • 北美洲
    • 我们
    • 加拿大
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 西班牙
    • 义大利
    • 欧洲其他地区
  • 拉丁美洲
    • 墨西哥
    • 巴西
    • 阿根廷
    • 拉丁美洲其他地区
  • 亚太
    • 中国
    • 印度
    • 日本
    • 韩国
    • 亚太其他地区
  • 中东和非洲

第九章：竞争格局与市场定位

  • 竞争概况和主要市场参与者
  • 市占率分析与定位矩阵
  • 策略伙伴关係、併购
  • 产品组合和创新的关键发展
  • 公司基准化分析

第十章：公司简介

  • Abbott
    • 公司概况
    • 产品组合
      • 产品描述
      • 产品关键绩效指标 (KPI)
      • 历史和预测产品销售量
      • 产品销售量
  • Financial Overview
    • 公司收入
      • 地区收入份额
      • 收入预测
      • 关键进展
      • 合併与收购
      • 关键产品开发活动
      • 监管部门批准等
      • SWOT 分析
    • Dexcom 公司
    • F. 霍夫曼-罗氏有限公司
    • 美敦力
    • Insulet 公司。
    • Tandem 糖尿病护理公司
    • Ascensia 糖尿病照护控股公司。
    • LifeScan IP 控股有限责任公司
    • 矩阵
    • Ypsomed AG（非详尽列表）

第 11 章：假设与研究方法

  • 资料收集方法
  • 数据三角测量
  • 预测技术
  • 数据验证和确认

第 12 章：附录

简介目录
Product Code: MD2392

The global digital diabetes management market reached US$ 14.58 billion in 2024 and is expected to reach US$ 33.26 billion by 2033, growing at a CAGR of 9.7 % during the forecast period of 2025-2033.

The global digital diabetes management market leverages digital technologies, such as devices, software, and services, to improve diabetes management and monitoring. This includes tools like continuous glucose monitors (CGMs), insulin pumps, mobile apps, and cloud-based platforms. These technologies work together to collect, analyze, and share data on a patient's health metrics, providing real-time insights that enable patients and healthcare providers to make informed decisions about diabetes management. The market aims to empower patients to control their glucose levels better, reduce complications, and improve overall health outcomes.

Market Dynamics: Drivers & Restraints

Technological Advancements in Diabetes Digital Health

Technological advancements play a key role in driving the growth of the digital diabetes management market. Innovations such as continuous glucose monitors (CGMs), smart insulin pumps, wearable devices, and AI-powered diabetes management apps are transforming how diabetes is monitored and managed. These technologies provide real-time, personalized data on blood glucose levels, enabling patients and healthcare providers to make better-informed decisions. For instance, AI and big data analytics help refine insulin delivery algorithms and offer individualized treatment recommendations, improving both short- and long-term diabetes management.

Technological advancements are revolutionizing diabetes care by providing effective tools for managing the condition. One key focus is maintaining optimal glucose levels consistently. Digital health tools, including connected insulin pens, portable A1C monitors, and mobile apps, are making it easier for patients to manage their diabetes outside of hospital settings. These mobile applications allow healthcare providers to create personalized treatment plans based on real-time data, ensuring better control over blood glucose levels and potentially reducing long-term health risks.

Another breakthrough in diabetes management is the automated insulin delivery (AID) system, which combines continuous glucose monitors (CGMs) and insulin pumps to automatically adjust insulin levels based on real-time glucose data. This system offers more precise control over blood sugar levels, reducing the burden on patients. Additionally, portable A1C monitors allow individuals to measure their A1C levels at home, providing an essential marker for assessing long-term diabetes control. These advancements contribute significantly to personalized care, enabling patients to better manage their condition with fewer hospital visits.

For instance, in February 2024, Kakao Healthcare launched a new AI-powered diabetes management app called PASTA (Personalized, Accessible, Supportive, Tech-enabled, and Affordable). This app is designed to help people with diabetes and other chronic conditions manage their health more effectively. It integrates with continuous glucose monitoring (CGM) devices, such as i-SENS's CareSens Air and Dexcom's G7, to provide real-time data on blood glucose levels. All these factors demand the global digital diabetes management market.

High Cost of Devices and Technology

The high cost of devices and technology remains a significant restraint in the global digital diabetes management market. Insulin pumps, continuous glucose monitors (CGMs), and other advanced digital tools can be quite expensive, as per National Center for Biotechnology Information (NCBI) data in July 2024, with some insulin pumps costing between $4,500 and $6,500, not including associated consumables. This price tag can be a barrier for patients, especially those without health insurance, limiting their access to essential diabetes management technology.

Moreover, although these devices improve patient outcomes by providing real-time data and better control over glucose levels, studies have shown that insulin pumps may not always be the most cost-effective option compared to multiple daily injections (MDI), especially for those with type 1 diabetes. As a result, the global diabetes management market is expanding rapidly. The above factors are limiting the market growth.

Segment Analysis

The global digital diabetes management market is segmented based on product type, modality, end-user, and region.

Product Type:

The continuous glucose monitoring (CGM) systems segment from product type is expected to dominate the digital diabetes management market with the highest market share

Continuous glucose monitoring (CGM) systems are a major driver of the growth in the global digital diabetes management market. These devices enable patients to monitor their glucose levels in real time throughout the day without the need for frequent fingerstick testing. CGMs provide critical data on glucose fluctuations, offering patients a comprehensive view of their glucose patterns. This real-time data helps individuals with diabetes make more informed decisions about their insulin dosage, diet, and exercise, contributing to better control over blood sugar levels and fewer complications in the long run.

The increasing accuracy, affordability, and convenience of CGMs have significantly boosted their adoption, especially as these devices now integrate with other diabetes management tools, like insulin pumps and mobile apps. Many CGM systems are now more compact, with advanced features such as alarms for high or low glucose levels, and they often work wirelessly with smartphones, providing patients with accessible and personalized management options.

As more people seek non-invasive, continuous monitoring options, CGMs are becoming a key element in both type 1 and type 2 diabetes management. Their widespread use is a major factor driving the expansion of the digital diabetes management market, particularly as healthcare providers leverage data from CGMs to improve treatment outcomes and patient engagement.

For instance, in August 2024, Medtronic announced FDA approval for its Simplera continuous glucose monitor (CGM), marking a significant innovation in diabetes care. Simplera is Medtronic's first all-in-one, disposable CGM that is half the size of its previous models. Designed for simplicity, it features an easy two-step insertion process, making it ideal for individuals using multiple daily insulin injections (MDI).

It eliminates the need for overtape, offering a more discreet and comfortable wear experience. Additionally, the Simplera system integrates seamlessly with the InPen smart insulin pen and is compatible with Medtronic's MiniMed 780G automated insulin delivery system. These factors have solidified the segment's position in the global digital diabetes management market.

Geographical Analysis

North America is expected to hold a significant position in the global digital diabetes management market with the highest market share

The high prevalence of diabetes in the United States, with nearly 16% of adults diagnosed according to the Centers for Disease Control and Prevention (CDC), is a significant driving factor for the growth of the North American digital diabetes management market.

As the number of diabetes cases continues to rise, there is an increasing demand for effective, efficient, and accessible management solutions. Digital health technologies, such as continuous glucose monitoring (CGM) systems, smart insulin pumps, and mobile apps, offer patients real-time data and personalized feedback that can significantly improve diabetes control, reducing complications associated with the disease.

The integration of AI and machine learning into diabetes management devices allows for smarter, more personalized treatment. These technologies help optimize insulin dosing, offer predictive insights, and reduce the frequency of diabetes-related complications. Moreover, the development of wearable devices, such as insulin pumps and glucose sensors, that are more user-friendly and connected to mobile apps enhances patient engagement and self-management.

For instance, in February 2025, Owens & Minor launched the ByramConnect digital health platform, designed to assist individuals with diabetes and other chronic health conditions. This platform is powered by the Welldoc App, which uses artificial intelligence to provide personalized coaching, self-tracking, and clinically relevant insights. It helps individuals manage conditions like type 1 and type 2 diabetes, as well as related conditions such as hypertension, cardiovascular risks, and weight management

Competitive Landscape

The major global players in the digital diabetes management market include Abbott, Dexcom, Inc., F. Hoffmann-La Roche Ltd, Medtronic, and Insulet Corporation. Tandem Diabetes Care, Inc., Ascensia Diabetes Care Holdings AG., LifeScan IP Holdings, LLC., AgaMatrix, and Ypsomed AG among others.

Key Developments

  • In August 2024, Insulet Corporation's Omnipod 5 Automated Insulin Delivery System was FDA-cleared for use by adults with type 2 diabetes, making it the first and only tubeless automated insulin delivery (AID) system approved for both type 1 and type 2 diabetes management.
  • In December 2023, Tandem Diabetes Care launched the full U.S. rollout of its revamped diabetes management platform, Tandem Source. This platform integrates several features from its previous systems, such as t:connect and t:connect HCP, and combines them with enhanced data reporting tools.
  • In August 2023, Welldoc, a digital health leader revolutionizing chronic care, announced the receipt of its 11th 510(k) clearance from the Food and Drug Administration (FDA) for its award-winning diabetes digital health solution, BlueStar. This clearance immediately follows Welldoc's 10th 510(k) clearance announcement earlier this month, solidifying the company's continued leadership in chronic care innovation.
  • In August 2023, Nemaura Medical's sugarBEAT received approval from the Saudi Food and Drug Authority (SFDA), marking a significant milestone in the Middle East market. This wearable, non-invasive glucose sensor offers continuous glucose monitoring (CGM) for diabetes and pre-diabetes management.

Why Purchase the Report?

  • Pipeline & Innovations: Reviews ongoing clinical trials and product pipelines and forecasts upcoming advancements in medical devices and pharmaceuticals.
  • Product Performance & Market Positioning: Analyzed product performance, market positioning, and growth potential to optimize strategies.
  • Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
  • Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
  • Market Updates & Industry Changes: This covers recent regulatory changes, new policies, and emerging technologies.
  • Competitive Strategies: Analyze competitor strategies, market share, and emerging players.
  • Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
  • Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
  • Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
  • Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient product delivery.
  • Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
  • Post-market Surveillance: Uses post-market data to enhance product safety and access.
  • Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.

The global digital diabetes management market report delivers a detailed analysis with 62 key tables, more than 54 visually impactful figures, and 176 pages of expert insights, providing a complete view of the market landscape.

Target Audience 2024

  • Manufacturers: Pharmaceutical, Medical Device, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
  • Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
  • Technology & Innovation: AI/Robotics Providers, R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
  • Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
  • Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
  • Supply Chain: Distribution and Supply Chain Managers.
  • Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
  • Academic & Research: Academic Institutions

Table of Contents

1. Market Introduction and Scope

  • 1.1. Objectives of the Report
  • 1.2. Report Coverage & Definitions
  • 1.3. Report Scope

2. Executive Insights and Key Takeaways

  • 2.1. Market Highlights and Strategic Takeaways
  • 2.2. Key Trends and Future Projections
  • 2.3. Snippet by Product Type
  • 2.4. Snippet by Modality
  • 2.5. Snippet by End-User
  • 2.6. Snippet by Region

3. Dynamics

  • 3.1. Impacting Factors
    • 3.1.1. Drivers
      • 3.1.1.1. Technological Advancements in Diabetes Digital Health
      • 3.1.1.2. Rising Prevalence of Diabetes
    • 3.1.2. Restraints
      • 3.1.2.1. High Cost of Devices and Technology
      • 3.1.2.2. Data Privacy and Security Concerns
    • 3.1.3. Opportunity
      • 3.1.3.1. Expansion in Emerging Markets
    • 3.1.4. Impact Analysis

4. Strategic Insights and Industry Outlook

  • 4.1. Market Leaders and Pioneers
    • 4.1.1. Emerging Pioneers and Prominent Players
    • 4.1.2. Established leaders with largest-selling Brand
    • 4.1.3. Market leaders with established Product
  • 4.2. CXO Perspectives
  • 4.3. Latest Developments and Breakthroughs
  • 4.4. Case Studies/Ongoing Research
  • 4.5. Regulatory and Reimbursement Landscape
    • 4.5.1. North America
    • 4.5.2. Europe
    • 4.5.3. Asia Pacific
    • 4.5.4. Latin America
    • 4.5.5. Middle East & Africa
  • 4.6. Porter's Five Forces Analysis
  • 4.7. Supply Chain Analysis
  • 4.8. Patent Analysis
  • 4.9. SWOT Analysis
  • 4.10. Unmet Needs and Gaps
  • 4.11. Recommended Strategies for Market Entry and Expansion
  • 4.12. Scenario Analysis: Best-Case, Base-Case, and Worst-Case Forecasts
  • 4.13. Pricing Analysis and Price Dynamics
  • 4.14. Key Opinion Leaders

5. Digital Diabetes Management Market, By Product Type

  • 5.1. Introduction
    • 5.1.1. Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 5.1.2. Market Attractiveness Index, By Product Type
  • 5.2. Smart Glucose Meters*
    • 5.2.1. Introduction
    • 5.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 5.3. Continuous Glucose Monitoring (CGM) Systems
  • 5.4. Smart Insulin Pens
  • 5.5. Smart Insulin Pumps
  • 5.6. Insulin Patches and Closed-loop Pumps
  • 5.7. Others

6. Digital Diabetes Management Market, By Modality

  • 6.1. Introduction
    • 6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Modality
    • 6.1.2. Market Attractiveness Index, By Modality
  • 6.2. Wearable*
    • 6.2.1. Introduction
    • 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 6.3. Handheld

7. Digital Diabetes Management Market, By End-User

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 7.1.2. Market Attractiveness Index, By End-User
  • 7.2. Home Care Settings*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.3. Hospitals and Diabetes Clinics
  • 7.4. Others

8. Digital Diabetes Management Market, By Regional Market Analysis and Growth Opportunities

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 8.1.2. Market Attractiveness Index, By Region
  • 8.2. North America
    • 8.2.1. Introduction
    • 8.2.2. Key Region-Specific Dynamics
    • 8.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 8.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Modality
    • 8.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 8.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 8.2.6.1. U.S.
      • 8.2.6.2. Canada
  • 8.3. Europe
    • 8.3.1. Introduction
    • 8.3.2. Key Region-Specific Dynamics
    • 8.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 8.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Modality
    • 8.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 8.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 8.3.6.1. Germany
      • 8.3.6.2. U.K.
      • 8.3.6.3. France
      • 8.3.6.4. Spain
      • 8.3.6.5. Italy
      • 8.3.6.6. Rest of Europe
  • 8.4. Latin America
    • 8.4.1. Introduction
    • 8.4.2. Key Region-Specific Dynamics
    • 8.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 8.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Modality
    • 8.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 8.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 8.4.6.1. Mexico
      • 8.4.6.2. Brazil
      • 8.4.6.3. Argentina
      • 8.4.6.4. Rest of Latin America
  • 8.5. Asia-Pacific
    • 8.5.1. Introduction
    • 8.5.2. Key Region-Specific Dynamics
    • 8.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 8.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Modality
    • 8.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 8.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 8.5.6.1. China
      • 8.5.6.2. India
      • 8.5.6.3. Japan
      • 8.5.6.4. South Korea
      • 8.5.6.5. Rest of Asia-Pacific
  • 8.6. Middle East and Africa
    • 8.6.1. Introduction
    • 8.6.2. Key Region-Specific Dynamics
    • 8.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 8.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Modality
    • 8.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

9. Competitive Landscape and Market Positioning

  • 9.1. Competitive Overview and Key Market Players
  • 9.2. Market Share Analysis and Positioning Matrix
  • 9.3. Strategic Partnerships, Mergers & Acquisitions
  • 9.4. Key Developments in Product Portfolios and Innovations
  • 9.5. Company Benchmarking

10. Company Profiles

  • 10.1. Abbott*
    • 10.1.1. Company Overview
    • 10.1.2. Product Portfolio
      • 10.1.2.1. Product Description
      • 10.1.2.2. Product Key Performance Indicators (KPIs)
      • 10.1.2.3. Historic and Forecasted Product Sales
      • 10.1.2.4. Product Sales Volume
  • 10.2. Financial Overview
    • 10.2.1. Company Revenue
      • 10.2.1.1. Geographical Revenue Shares
      • 10.2.1.1.1. Revenue Forecasts
      • 10.2.1.2. Key Developments
      • 10.2.1.2.1. Mergers & Acquisitions
      • 10.2.1.2.2. Key Product Development Activities
      • 10.2.1.2.3. Regulatory Approvals, etc.
      • 10.2.1.3. SWOT Analysis
    • 10.2.2. Dexcom, Inc.
    • 10.2.3. F. Hoffmann-La Roche Ltd
    • 10.2.4. Medtronic
    • 10.2.5. Insulet Corporation.
    • 10.2.6. Tandem Diabetes Care, Inc.
    • 10.2.7. Ascensia Diabetes Care Holdings AG.
    • 10.2.8. LifeScan IP Holdings, LLC.
    • 10.2.9. AgaMatrix
    • 10.2.10. Ypsomed AG (LIST NOT EXHAUSTIVE)

11. Assumptions and Research Methodology

  • 11.1. Data Collection Methods
  • 11.2. Data Triangulation
  • 11.3. Forecasting Techniques
  • 11.4. Data Verification and Validation

12. Appendix

  • 12.1. About Us and Services
  • 12.2. Contact Us